2025 Europe Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 Europe Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in Europe are GSK plc, Sanofi SA, Alnylam Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc. These companies lead the market due to their extensive research and development efforts, collaborations, and product pipelines focused on antisense oligonucleotide (ASO) and RNA interference (RNAi) therapies targeting various disorders, including genetic diseases, cancer, and cardiovascular conditions.
GSK plc and Sanofi SA, as established pharmaceutical giants, leverage their European presence and partnerships to accelerate clinical development and commercialization. Alnylam Pharmaceuticals Inc, a global RNAi pioneer, expanded collaborations in Central and Eastern Europe to enhance access to RNAi therapeutics. Ionis Pharmaceuticals is noted for its advances in antisense technology and strategic alliances, for example with AstraZeneca, to develop novel antisense medicines. Collectively, these companies drive the European market growth, which is projected to reach nearly USD 2.8 billion by 2030, with a CAGR above 18%.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in Europe are GSK plc, Sanofi SA, Alnylam Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc. These companies lead the market due to their extensive research and development efforts, collaborations, and product pipelines focused on antisense oligonucleotide (ASO) and RNA interference (RNAi) therapies targeting various disorders, including genetic diseases, cancer, and cardiovascular conditions.
GSK plc and Sanofi SA, as established pharmaceutical giants, leverage their European presence and partnerships to accelerate clinical development and commercialization. Alnylam Pharmaceuticals Inc, a global RNAi pioneer, expanded collaborations in Central and Eastern Europe to enhance access to RNAi therapeutics. Ionis Pharmaceuticals is noted for its advances in antisense technology and strategic alliances, for example with AstraZeneca, to develop novel antisense medicines. Collectively, these companies drive the European market growth, which is projected to reach nearly USD 2.8 billion by 2030, with a CAGR above 18%.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
